Liminatus Pharma to acquire InnocsAI in stock merger valued at ~$320M

Liminatus Pharma, Inc.

1.6B shares at $0.20/share ($320M aggregate) plus contingent value rights of 20% of future net proceeds from asset sale.
Assets include CAR-T pipeline: IBC101 (Phase 1/2a in Korea for DLBCL) and preclinical INC101 for solid tumors.
CEO Chris Kim also controls Valetudo Therapeutics LLC, a member of InnocsAI, making the transaction a related-party deal.
Closing targeted by Dec 31, 2026, subject to stockholder approvals and other customary conditions.
Liminatus to file a registration statement/proxy statement for the stockholder vote.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Liminatus Pharma, Inc. entered into Merger Agreement with InnocsAI LLC valued at 1,600,000,000 shares of the Company’s common stock, at an issue price of $0.20 per share (effective 2026-05-17).

Action: entry
Agreement: merger
Counterparty: InnocsAI LLC
Value: 1,600,000,000 shares of the Company’s common stock, at an issue price of $0.20 per share
Effective: 2026-05-17

Exact text from the filing

On May 17, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a Merger Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”) with InnocsAI LLC, Delaware limited liability company (“InnocsAI”), and NamChul Jung, an individual, as the representative of the members of InnocsAI.

View on SEC.gov

Browse all material agreements →

Liminatus Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-064585

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.